Zenotech Laboratories

Zenotech Laboratories Net Debt/Equity

The Net Debt to Equity Ratio of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -0.28. In the previous year, Net Debt to Equity Ratio was -0.22 — a change of 27.76% (lower).

Net Debt/Equity

-0.28

YoY

27.76%

Last updated:

Net Debt to Equity Ratio of Zenotech Laboratories is 2025 -0.28 . Net Debt to Equity Ratio of Zenotech Laboratories was 2024 -0.22 . It decreases by 27.76% lower compared to the previous year.

The Zenotech Laboratories Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-0.68 INR
Jan 1, 2019
0.18 INR
Jan 1, 2020
0.35 INR
Jan 1, 2021
0.37 INR
Jan 1, 2022
0.05 INR
Jan 1, 2023
0.00 INR
Jan 1, 2024
-0.22 INR
Jan 1, 2025
-0.28 INR
The Zenotech Laboratories Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.28+27.76%
-0.22—
0.00-100.00%
0.05-86.99%
0.37+5.34%
0.35+95.56%
0.18-126.79%
-0.68-12.15%
-0.77-30.43%
-1.11-45.24%
-2.02-70.61%
-6.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Net Debt to Equity Ratio of Zenotech Laboratories is -0.28 in 2025.

Net Debt to Equity Ratio of Zenotech Laboratories changed from -0.22 to -0.28, representing a 27.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories